Tamoxifen induces deregulation of [Ca2+] in human breast cancer cells

Anticancer Research

Volumn 17, Issue 2 A, 1997, Pages 1167-1174

  Jain, Pramod T ^a,b   Trump, Benjamin F ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b Sanger Hall ^*  (United States)

Author keywords

Antiestrogens; Antiproliferative activity; Cytotoxicity; MCF 7 cells; Tumor promotion

Indexed keywords

CALCIUM ION; CALMODULIN; IONOMYCIN; PROTEIN KINASE; PROTEIN KINASE C; TAMOXIFEN;

ARTICLE; BREAST CANCER; CALCIUM CELL LEVEL; CARCINOGENESIS; CELL STRAIN MCF 7; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG RESISTANCE; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; ONCOGENE; PRIORITY JOURNAL; TUMOR PROMOTION;

BREAST NEOPLASMS; CALCIUM; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0030981833     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Osborne CK, Coronado EB, Robinson JR: Human breast cancer in athymic mouse: cytostatic effects of long-term antiestrogen therapy. Eurx Cancer Clin Oncol 23: 1189-1196, 1987.
2. Gottardis MM, Jordan VC: Development of tamoxifen-stimulated growth of MCF-7 tumor in athymic mouse after long-term tamoxifen administration. Cancer Res 48: 5183-5188, 1988.
3. Gottardis MM, Robinson SP, and Jordan VC: Estradiol stimulated growth of MCF-7 tumors Implanted in athymie mice: a model to study the tumoristatic action of tamoxifen. J Steroid Biochem 30: 311-314, 1988.
4. Bardon S, Vignon F, Derocq D, Rochefort H: The antiproliferative effect of tamoxifen in breast cancer cells: Mediation by the estrogen receptors. Molecular Cellular Endocrinology 35: 89-96, 1984.
5. Cerutti PA: Prooxidant states and tumor promotion. Science 227: 375-381, 1985
6. Cerutti PA, Trump BF: Inflammation and oxidative stress in carcinogenesis. Cancer Cells.3: 1-7, 1991.
7. Cerutti PA: Response modification in carcinogenesis. Environ Health Pcrspect 82: 39-43, 1989.
8. Jain PT, Chung SH, Berezesky IK. Amstad P. Cerutti PA and Trump BF: Differential ctoioxicity in mouse epidermal JB6 cells: A potential mechanism for oxidani tumor promotion. Molecular Carcinogenesis 11: 164-169, 1994.
9. 2+ elevation induced by henzoyl peroxide precedes higher cell death of non-promotable compared to promotable JB6 cells. in Vitro Toxicology 8: 251-261, 1995.
10. Trump BF, Jain PT, Phelps PC, Chang SH and Berezesky IK: Calcium measurements in the assessment in vitro toxicity. In: In vitro toxicology mechanism and new technology (Alternative methods in toxicology series), A.M. Goldberg, Ed, Mary Ann Liebert, Inc, Publishers, New York, Vol. 9. p. 175-184, 1993.
11. i and cell death in vivo: a study using the ced-1 mutant strain of C. Elegans Toxicologic Pathology 21: 572-583, 1993.
12. O'Brian CA, Liskamp RM: Solomon D H. Weinstein I B. Inhibition of protein kinase C by tamoxifen. Cancer Res 45: 2462-65, 1985.
13. Bouhoute A, Leclercq G: Antagonistic effect of triphenylethylenic antiestrogens on the association of estrogen receptor to calmodulin. Biochem Biophys Res Commun 184: 1432-40, 1992.
14. Castoria G, Migliaccio A, Nola E, Auricchio F: In vitro interaction of estradiol receptor with Ca2+-calmodulirl.Mol Endocrinol 2: 167-177, 1988.
15. Edashige K, Sato EF, Akimaru K, Yoshioka T: Utsumi K: Nonsteroidal antiestrogen suppresses protein kinase C-its inhibitory effect on interaction of substrate protein with membrane. Cell Struct Funct 76: 273-281, 1991.
16. Gupta V, Kamath NT, Kalcevic GT, Singh SV: Potentiation of tamoxifen activity by verapamil in a human breast cancer cell line. Biochem Pharmacol 47: 1701-4, 1994.
17. Wei JW, Hickie RA, Klaassen DJ: Inhibition of human breast cancer colony formation by anticalmodulin agents: Trifluoperazine. W-7, and W-13. Cancer Chem and Pharmacol 11: 86-90, 1983.
18. CIarke R, van den Berg HW, Murphy RF: Reduction of the membrane fluidity of human breast cancer cells by tamoxifen and 17 betaestradiol. J Natl Cancer Inst 82: 1702-1705, 1990.
19. Wiseman H: Tamoxifen: new membrane-mediated mechanisms of action and therapeutic advances. Trends Pharmacol Sci 75: 839, 1994.
20. Lipton A: The anti-oestrogen tamoxifen is a calcium antagonist in perfused rat mesentery. Cancer Chemother Pharmacol 20: 125-127, 1987.
21. i-A Novel Antiestrogenic Mechanism In Human Breast Cancer Cells. Proc. Am. Assoc. Cancer Res 1996.
22. Jain PT and Pento JT: Growth medium for the evaluation hntiestrogenic compounds in MCF-7 cell-culture. Method Find. Exp. Clin. Pharmacol 13: 595-598, 1991.
23. Jain PT and Pento JT: A vehicle for the evaluation of Hydrophobic compounds in cell culture. Res Comn Pathol Pharmacol 74: 105-116, In. 1991.
24. Vandewalle B: Calcium regulation of heparan sulfate proteoglycans in breast cancer cells. J Cancer Res Clin Oncol 720: 389-392, 1994.
25. Thomas DB: Mammographic calcifications and risk of subsequent breast cancer. J Natl Cancer Inst 85: 230-5, 1993.
26. Jain PT, Yamamoto N, Berezesky IK and Trump BF: Immediate early gene expression in mouse epidermal JB6 cells. The Pharmacologist 35: 172, 1993.
27. Hyder SM, Stancel GM, Nawaz Z, McDonnell DP, Loose-Mitchell D S: Identification of an estrogen response element in the 3'-flanking region of the murine c-fos protooncogene. J Biol Chem 267: 18047- 54, 1992.
28. Nephew KP, Polek TC, Akcali KC, Khan SA: The antiestrogen tamoxifen induces c-fos and jun-B, but not c-jun or jun-D, protooncogenes in the rat. Endocrinology 133: 419-22, 1993.
29. Kirkland JL, Murthy L, Stancel GM: Tamoxifen stimulates expression of the c-fos proto-oncogene in rodent, Mol Pharmacol 43: 70914, 1993.
30. Chien CH, Wang FF, Hamilton TC: Transcriptional activation of cmyc proto-oncogene by estrogen in human ovarian cancer cells. Mol Cell Endocrinol 99: 11-19, 1994.
31. Le Roy X, Escot C, Brouillet JP, Theillet C, Maudelonde T, SimonyLafontaine J. Pujol H. Rochefort H: Decrease of c-erbB-2 and c-myc RNA levels in tamoxifen-treated breast cancer. Oncogene 6: 4317, 1991.
32. Dubik D, Dembinski TC, Shiu RP: Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells. Cancer Res 47: 6517-6521, 1987.
33. Dubik D, Shiu RP: Transcriptional regulation of c-myc oncogene expression by estrogen in hormone-responsive human breast cancer cells. J Biol Chem 263: 12705, 1988.
34. Dubik D, Shiu RP: Mechanism of estrogen activation of c-myc oncogene expression. Oncogene 7: 1587-1594, 1992.
35. i and antiproliferative activity of estradiol in human breast cancer MCF-7 cells. FASEB J 1996.
36. Aronica SM, Kraus WL, Katzenellenbogen BS: Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMPregulated gene transcription. Proc Natl Acad Sci USA 9: 8517-8521, 1994.
37. Morley P, Whitfield JF, Vanderhyden BC, Tsang BK, Schwartz JL: A new, nongenomic estrogen action: the rapid release of intracellular calcium. Endocrinology 131: 1305-1312, 1992.